Event Type: Q2 and H1 FY27 Earnings Conference Call
Event Date and Time: November 17, 2026. The specific time was not mentioned in the transcript.
Purpose: Discussion of the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
Management Participants:
- Dr. Nikhil Kelkar – Joint Managing Director
- Mr. Vikram Kelkar – Managing Director
- Mr. Soman Jana – Chief Financial Officer
- Adfactors PR – Investor Relations Advisors
Availability of Materials: The transcript of the earnings call was disclosed to the exchanges and is also available on the company's website at www.hexagonnutrition.com.
Compliance Statement: The conference call contained forward-looking statements based on the company's beliefs and expectations as of the date of the call, which are not a guarantee of future performance.
Financial Period Discussed: Q2 (Quarter ended September 30, 2026) and H1 (Half year ended September 30, 2026) of FY 2026-27.
Key Financial Highlights from Management Commentary:
- H1 FY27 Revenue: ₹214 crores, up 27.3% YoY (from ₹168 crores last year).
- Q2 FY27 Revenue: ₹109.7 crores, up 15.2% YoY and 5.1% QoQ.
- H1 FY27 EBITDA: ₹22.7 crores (₹23.7 crores before an exceptional loss of ₹1.1 crores on disposal of plant and equipment).
- H1 FY27 Profit After Tax (PAT): ₹16.2 crores (broadly in line with ₹16.6 crores in H1 last year).
- Q2 FY27 Gross Profit Margin: 47%, an improvement of 310 basis points from 43.9% in Q1 FY27.
- Basic Earnings Per Share (EPS) for H1 was ₹1.41.
- The company is net cash positive by ~₹9 crores (Cash: ₹46.5 cr vs Borrowings: ₹37.4 cr).
- Inventory increased to ₹136 crores (from ₹84 crores in Mar'26) to secure raw material supply for H2 orders.
- Employee cost was 14.7% of revenue, up from 13.3%, due to investments in field force and other capabilities.
- Capital expenditure in H1 was ₹4 crores. A further capex of ~₹25 crores is planned for the reconstruction of the Nashik Premix Facility.
Strategic and Operational Updates:
- Growth Drivers: Growth was attributed to strong performance in both branded and premix businesses.
- Margin Improvement Plan: A 3-part plan is in place to improve margins: 1) Price increases on branded products (benefits expected in 1-2 quarters), 2) Secured longer-term raw material contracts, 3) Focus on higher-margin products and customers.
- Capacity Utilization: Blended utilization was around 30% in H1 (Nashik: ~55%, Chennai: ~25%, Tuticorin: ~26%).
- Order Book: The total order book stands at ₹100 crores, with ₹75 crores expected to be shipped in H2 FY27.
- Guidance: Management maintained its full-year revenue growth guidance of 20-25% YoY.
- New Product: Collaboration with Particles for Humanity on a stable form of Vitamin A+ for new geographies.
- Geographic Revenue Mix: Approximately 50-55% domestic, the remainder from exports.
- Field Force: The branded business field force has been expanded to 270 representatives.
Additional Notes Section
- The document is a regulatory filing containing the transcript of the earnings conference call.
- The transcript includes a full question-and-answer session with analysts and investors.
- No new unpublished price sensitive information (UPSI) was indicated to have been shared during the call; the discussion was based on declared results.